SHP Substrate 1 (PZR): A Central Signalling Hub Controlling Diverse Immune‑Cell Biological Outputs

Structural Architecture and Multi‑Layered Expression‑Regulatory Mechanisms

SHP Substrate 1, also annotated PZR, constitutes a 272‑amino‑acid type‑I transmembrane glycoprotein functioning as primary physiological substrate for SHP‑1 and SHP‑2 protein‑tyrosine‑phosphatases. Its modular architecture encompasses two extracellular immunoglobulin‑like domains, a 23‑residue hydrophobic transmembrane helix, plus an intracellular tail containing ITIM (Y241) and ITSM (Y263) tyrosine‑based regulatory motifs. Non‑phosphorylated intracellular segments adopt flexible disordered conformations; tyrosine phosphorylation triggers substantial structural rearrangement, forming high‑affinity binding surfaces for SHP‑SH2‑domain modules to assemble functional signal‑transduction complexes.

Its transcript abundance displays pronounced tissue‑specific and developmental‑stage‑dependent patterns within hematopoietic cell populations. Expression peaks inside hematopoietic stem‑cell compartments and declines progressively as myeloid and B‑lymphocyte populations reach terminal maturation. Transcription factors PU.1, GATA1 and C/EBPα interact with promoter‑region elements to establish hematopoietic‑lineage‑biased transcriptional programmes. Epigenetic repression via promoter‑targeted DNA‑methylation suppresses transcription within non‑hematopoietic tissues. Post‑transcriptional fine‑tuning is mediated by microRNA species including miR‑155 and miR‑181 family members, which associate with 3’‑UTR sequences to accelerate target‑mRNA degradation and dynamically adjust intracellular protein abundance.

Multi‑Dimensional Functions Within Immune‑Receptor Checkpoint‑Signalling Circuits

SHP Substrate 1 mediates downstream inhibitory signal propagation upon engagement of immune inhibitory receptors such as PD‑1, CTLA‑4 and KIR immune‑receptor complexes. ITIM/ITSM‑located tyrosine residues undergo rapid phosphorylation following receptor‑ligand ligation, recruiting cytosolic SHP‑1 and SHP‑2 phosphatases toward plasma‑membrane signalosomes. Recruited phosphatases execute de‑phosphorylation upon proximal signalling mediators including ZAP70, Syk and PI3K to attenuate activating‑receptor signal flows. Experimental genetic‑model data illustrate that PD‑1‑driven proliferative suppression drops more than 60 % inside SHP‑Substrate‑1‑deficient T‑cell populations, whereas protein over‑expression reduces T‑cell responsiveness by 3‑4‑fold. Phosphorylated SHP Substrate 1 allosterically elevates intrinsic SHP‑2 catalytic activity by 5‑8‑fold, furnishing potent signal‑dampening capacity for maintaining immune‑tolerance homeostasis.

This molecule executes context‑dependent dual regulatory effects during innate‑immune inflammatory cascades. In macrophage experimental systems, SHP Substrate 1 restrains excessive NF‑κB‑driven transcriptional outputs downstream of TLR‑family pattern‑recognition receptors. SHP‑Substrate‑1‑deficient macrophages exhibit 2‑fold‑to‑3‑fold amplified NF‑κB activity alongside elevated TNF‑α and IL‑6 secretion upon LPS‑stimulation. It also constrains inflammasome outputs by hindering NLRP3 oligomerization and limiting pro‑form cytokine maturation and release. Myeloid‑specific knockout mice display 40‑50 % higher disease indices in experimental‑colitis pre‑clinical‑model assays. Its regulatory influence exhibits receptor‑selective preference; strong inhibitory effects target TLR4‑ and TLR9‑triggered pathways, while TLR3‑originated signalling remains comparatively unaffected.

Contributions to Immune‑Cell Differentiation and Immunometabolic Reprogramming

SHP Substrate 1 shapes thymic T‑cell maturation by tuning TCR‑signal‑strength thresholds governing positive‑ and negative‑selection developmental events. Thymic‑epithelial‑cell‑targeted transgenic over‑expression lowers CD4⁺ single‑positive thymocyte counts by approximately 30 %, concurrently expanding CD8⁺ single‑positive cell populations and reshaping overall TCR‑repertoire composition. During B‑cell ontogeny, it modulates pre‑BCR signal amplitude; genetic ablation causes pre‑B‑cell population expansion plus perturbed immunoglobulin light‑chain rearrangement dynamics. Regulatory‑T‑cell compartments express 5‑8‑fold higher SHP Substrate 1 levels relative to conventional effector‑T‑cell subsets. Conditional Treg‑specific gene‑knockout triggers rapid‑onset fatal auto‑immune pathology in experimental‑animal cohorts, confirming its indispensable role for sustaining peripheral immune‑tolerance states.

Beyond classical signal‑attenuation tasks, SHP Substrate 1 acts as a critical immunometabolism signalling node coupling receptor‑signalling to intracellular metabolic‑network remodelling. Within activated T‑lymphocytes, phosphorylated SHP Substrate 1 recruits SHP‑2 to de‑phosphorylate TSC2 polypeptides, releasing intrinsic mTORC1‑pathway suppression and boosting glycolytic‑gene transcriptional programmes for HK2 and LDHA. SHP‑Substrate‑1‑deficient T‑cells show 40 %‑reduced glucose‑uptake capacity alongside 35 %‑lower ATP yields, creating metabolic insufficiency restricting effector‑cell proliferation. Tolerogenic dendritic‑cell contexts witness SHP‑Substrate‑1‑driven AKT‑pathway inhibition, shifting cellular metabolic preference toward fatty‑acid‑oxidation programmes characteristic of immune‑suppressive cellular phenotypes. It additionally modulates glutaminase‑enzyme activity and glutathione biosynthetic output to govern intracellular anti‑oxidant defence balances.

Disease‑Associated Phenotypes and Diversified Basic‑Research Investigation Tool‑Sets

Dysregulated SHP Substrate 1 expression and phosphorylation correlate with multiple hematologic‑malignancy and auto‑immune‑disease model phenotypes. In chronic myeloid‑leukaemia experimental systems, BCR‑ABL oncogenic kinase signalling sustains persistently elevated SHP Substrate 1 tyrosine‑phosphorylation status. Bone‑marrow‑derived material from CML pre‑clinical‑model cohorts displays 3‑5‑fold higher SHP Substrate 1 abundance relative to baseline control specimens; expression further rises 2‑3‑fold during accelerated‑phase and blast‑crisis disease progression stages. Within DLBCL experimental‑model systems, GCB‑subtype tumour‑cells maintain comparatively high SHP Substrate 1 levels associated with more favourable response‑related read‑outs, while ABC‑subtype specimens exhibit diminished transcript quantities. In auto‑immune‑disease contexts, SLE‑model T‑cells manifest lowered SHP Substrate 1 abundance plus aberrant tyrosine‑phosphorylation profiles; GWAS‑derived datasets link SHP‑Substrate 1 locus polymorphisms to elevated disease‑susceptibility odds ratios.

Diversified experimental‑methodology portfolios support mechanistic dissection for this signalling‑hub molecule. Conventional whole‑organism and tissue‑restricted conditional‑knockout, transgenic‑over‑expression and epitope‑tag‑knock‑in animal‑model systems furnish powerful in‑vivo investigative infrastructure. Affinity‑purification‑coupled mass‑spectrometry proteomic workflows identify dozens of SHP‑Substrate‑1‑associated signalling‑complex constituents. SPR biosensing quantifies 0.1‑1 μM‑range KD binding‑affinities for phosphorylated peptide‑ligand‑SHP‑SH2‑domain interaction events. FRET and cross‑linking‑mass‑spectrometry capture real‑time conformational dynamics and higher‑order signal‑complex topological‑organization features. These multi‑modal experimental resources facilitate target‑oriented small‑molecule‑candidate exploratory‑screening for immunomodulatory‑basic‑research projects.

Phospho‑SHP‑2 Targeted Antibody Research Reagents from ANT BIO PTE. LTD

ANT BIO PTE. LTD supplies phospho‑SHP‑2‑specific immunodetection reagents supporting SHP‑Substrate‑1‑centered immune‑signal‑transduction mechanistic basic‑research assignments. Every antibody production lot undergoes peptide‑array epitope‑selectivity screening and multi‑assay functional‑validation before commercial release.

Catalog Table of Phospho‑SHP‑2 Research Antibody Reagents

Functional‑Validation Characteristics of ANT BIO PTE. LTD Phospho‑SHP‑2 Antibodies

S0B1093 recombinant rabbit monoclonal antibody selectively recognizes SHP‑2 Tyr542 phosphorylated epitope and displays minimal cross‑reactivity against unphosphorylated SHP‑2 protein molecules. S0G0015 antibody‑duo kit delivers pre‑matched reagent‑combinations to streamline laboratory assay‑assembly workflows. Validated biological sample matrices include immune‑cell lysates, in‑vitro re‑constituted kinase‑phosphatase biochemical‑reaction products, and transgenic‑model‑system cell‑extract specimens. Qualified experimental workflows encompass Western‑blot phosphoprotein quantification, immunoprecipitation complex‑capture and cell‑lysate‑based immuno‑detection for monitoring SHP‑2 activation status in SHP‑Substrate‑1‑driven signalling‑cascade studies.

Core Fundamental‑Research Applications for Phospho‑SHP‑2 Antibody Panel

1. Western‑blot read‑out monitoring of SHP‑2 Tyr542 phosphorylation activation status in SHP‑Substrate‑1 reconstituted biochemical assay‑systems

2. Immunoprecipitation capture of activated SHP‑2‑containing signal‑complexes for subsequent interactome proteomic‑identification experiments

3. Immune‑cell‑model‑system signalling studies quantifying SHP‑2 activation‑kinetics downstream of inhibitory‑receptor stimulation events

4. Biochemical compound‑screening assays evaluating small‑molecule modulator impacts on SHP‑2 phosphorylation‑activation responses

5. Orthogonal read‑out assays complementing SPR biosensor measurements characterizing SHP‑Substrate‑1‑SHP‑2 molecular‑interaction profiles

6. Phenotypic‑characterization work for gene‑knockout or over‑expression cell‑lines dissecting immune‑inhibitory‑signalling‑cascade outputs

Global Manufacturing & Compliance Standards

All phospho‑SHP‑2 antibody batches complete peptide‑epitope‑specificity profiling and multi‑platform functional‑performance‑verification prior to commercial‑product release. Manufacturing facilities adhere to ISO9001, ISO13485 and EU 98/79/EC certification specifications governing life‑science‑research‑reagent‑production‑protocols. In‑house application‑science teams supply detailed immuno‑assay‑SOP‑documents and curated SHP‑Substrate‑1 immune‑signalling‑reference‑publication‑resources. The broader reagent ecosystem includes additional PTM‑detection antibodies, recombinant‑proteins and ELISA‑kits supporting comprehensive immunology multi‑omics‑research pipelines.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.